Literature DB >> 10870511

An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

S J Veldhuyzen van Zanten1, N Flook, N Chiba, D Armstrong, A Barkun, M Bradette, A Thomson, F Bursey, P Blackshaw, D Frail, P Sinclair.   

Abstract

OBJECTIVES: To provide Canadian primary care physicians with an evidence-based clinical management tool, including diagnostic and treatment recommendations, for patients who present with uninvestigated dyspepsia. RECOMMENDATIONS: The management tool has 5 key decision steps addressing the following: (1) evidence that symptoms originate in the upper gastrointestinal tract, (2) presence of alarm features, (3) use of nonsteroidal anti-inflammatory drugs (NSAIDs), (4) dominant reflux symptoms and (5) evidence of Helicobacter pylori infection. All patients over 50 years of age who present with new-onset dyspepsia and patients who present with alarm features should receive prompt investigation, preferably by endoscopy. The management options for patients with uninvestigated dyspepsia who use NSAIDs regularly are: (1) to stop NSAID therapy and assess symptomatic response, (2) to treat with NSAID prophylaxis if NSAID therapy cannot be stopped or (3) to refer for investigation. Gastroesophageal reflux disease can be diagnosed clinically if the patient's dominant symptoms are heartburn or acid regurgitation, or both; these patients should be treated with acid suppressive therapy. The remaining patients should be tested for H. pylori infection, and those with a positive result should be treated with H. pylori-eradication therapy. Those with a negative result should have their symptoms treated with optimal antisecretory therapy or a prokinetic agent. VALIDATION AND EVIDENCE: Evidence for resolution of the dyspepsia symptoms was the main outcome measure. Supporting evidence for the 5 steps in the management tool and the recommendations for treatment were graded according to the strength of the evidence and were endorsed by consensus of committee members. If no randomized controlled clinical trials were available, the recommendations were based on the best available evidence. LITERATURE REVIEW: Evidence was obtained from MEDLINE searches for pertinent articles published from 1966 to October 1999. The searches focused on dyspepsia, diagnosis and treatment. Additional articles were retrieved through a manual search of bibliographies and abstracts from international gastroenterology conferences.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870511      PMCID: PMC1232536     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  171 in total

1.  Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis.

Authors:  C T Loy; L M Irwig; P H Katelaris; N J Talley
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

2.  Cisapride and fatal arrhythmia.

Authors:  D K Wysowski; J Bacsanyi
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

Review 3.  Helicobacter pylori infection and dyspepsia.

Authors:  D Armstrong
Journal:  Scand J Gastroenterol Suppl       Date:  1996

4.  Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement.

Authors:  P Bytzer; J M Hansen; T Havelund; A Malchow-Møller; O B Schaffalitzky de Muckadell
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-04       Impact factor: 2.566

5.  Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis.

Authors:  C M Bate; S M Griffin; P W Keeling; A T Axon; M W Dronfield; R W Chapman; D O'Donoghue; J Calam; J Crowe; R A Mountfords; D A Watts; M D Taylor; P D Richardson
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

6.  Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.

Authors:  P Ekström; L Carling; S Wetterhus; P E Wingren; O Anker-Hansen; G Lundegårdh; E Thorhallsson; P Unge
Journal:  Scand J Gastroenterol       Date:  1996-08       Impact factor: 2.423

7.  Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard.

Authors:  J C Thijs; A A van Zwet; W J Thijs; H B Oey; A Karrenbeld; F Stellaard; D S Luijt; B C Meyer; J H Kleibeuker
Journal:  Am J Gastroenterol       Date:  1996-10       Impact factor: 10.864

8.  Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.

Authors:  J Parsonnet; R A Harris; H M Hack; D K Owens
Journal:  Lancet       Date:  1996-07-20       Impact factor: 79.321

9.  High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs.

Authors:  S ten Wolde; B A Dijkmans; M Janssen; J Hermans; C B Lamers
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

10.  Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.

Authors:  A S Taha; N Hudson; C J Hawkey; A J Swannell; P N Trye; J Cottrell; S G Mann; T J Simon; R D Sturrock; R I Russell
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245

View more
  47 in total

1.  Update from the Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

2.  Dyspepsia, peptic ulcer disease, and esophageal reflux disease.

Authors:  Mark D Schwartz
Journal:  West J Med       Date:  2002-03

3.  Management of patients with uninvestigated dyspepsia.

Authors:  S Veldhuyzen van Zanten; N Flook; N Chiba
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

4.  Treating non-ulcer dyspepsia and H pylori.

Authors:  S J van Zanten
Journal:  BMJ       Date:  2000-09-16

5.  Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Authors:  John K Marshall; Paul V Grootendorst; Bernie J O'Brien; Lisa R Dolovich; Anne M Holbrook; Adrian R Levy
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

6.  AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns.

Authors:  Marilyn N Martinez; Iain McGilveray
Journal:  AAPS PharmSci       Date:  2003-10-23

7.  Symptoms resolution post-cholecystectomy: patient selection is very important.

Authors:  Vui Heng Chong
Journal:  J Gastrointest Surg       Date:  2012-02-11       Impact factor: 3.452

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 9.  Approach to managing undiagnosed chest pain: could gastroesophageal reflux disease be the cause?

Authors:  Nigel Flook; Peter Unge; Lars Agréus; Björn W Karlson; Staffan Nilsson
Journal:  Can Fam Physician       Date:  2007-02       Impact factor: 3.275

Review 10.  Clinical practice: diagnosis and evaluation of dyspepsia.

Authors:  David Yates Graham; Massimo Rugge
Journal:  J Clin Gastroenterol       Date:  2010-03       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.